LifeTech Scientific Corporation (1302) AI Stock Analysis

• Market Cap: HK$8.51B
• Dividend Yield: N/A
• Average Volume (3M): 26.58M
• Price to Earnings (P/E): 110.7
• Beta (1Y): 0.96
• Revenue Growth: 3.42%
• EPS Growth: -70.82%
• Country: HK
• Employees: 1,395
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.01
• Shares Outstanding: 4,631,712,400
• 10 Day Avg. Volume: 33,345,600
• 30 Day Avg. Volume: 26,582,987
• PEG Ratio: -1.85
• Price to Book (P/B): 1.64
• Price to Sales (P/S): 4.39
• P/FCF Ratio: 148.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: HK$2.00 ▲(5.26% Upside)

The overall stock score of 57 reflects a combination of strong financial performance but is weighed down by technical indicators and valuation concerns. The company's robust revenue growth and solid balance sheet are offset by declining margins and inconsistent cash flow. The technical analysis indicates bearish momentum, and the high P/E ratio suggests overvaluation, impacting the stock's attractiveness.

LifeTech Scientific Corporation Business Overview & Revenue Model

Company Description

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; manufacturing and trading of materials for hemp; staff training and internal personnel management business; information consulting for investors; and manufacturing and trading of medical devices, as well as technical, consulting, and technology services. It has operations in Mainland China, India, rest of Asia, Europe, South America, Africa, and internationally. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.

How the Company Makes Money

LifeTech Scientific Corporation generates revenue primarily through the sale of its medical devices and related products. The company's key revenue streams include direct sales of its cardiovascular devices, orthopedic implants, and surgical instruments to hospitals and healthcare institutions. Additionally, LifeTech engages in partnerships with healthcare providers and distributors to enhance its market reach and distribution capabilities. The firm also invests in research and development to create innovative products, which can lead to increased sales and revenue growth. Furthermore, the company may benefit from licensing agreements and collaborations that provide additional revenue opportunities through technology sharing and joint ventures.

LifeTech Scientific Corporation Financial Statement Overview

Summary

LifeTech Scientific Corporation demonstrates strong revenue growth and maintains a healthy balance sheet with low leverage. However, declining margins and inconsistent cash flow generation pose challenges that could affect long-term sustainability. The company should address operational efficiencies and cash flow stability to enhance financial performance.

Income Statement

LifeTech Scientific Corporation shows strong revenue growth with a notable increase from 2019 to 2024. The gross profit margin remains robust, indicating efficient cost management and strong competitive positioning. However, a declining EBIT margin from 2023 to 2024 suggests increased operational costs, impacting profitability. The net profit margin has slightly decreased over the years, indicating some pressure on bottom-line growth.

Balance Sheet

The company's balance sheet is solid with a low debt-to-equity ratio, suggesting minimal leverage risk. The equity ratio is high, indicating strong capitalization and stability. However, the slight decrease in return on equity (ROE) suggests that profitability relative to shareholders' equity is under pressure, which can be a concern if it continues.

Cash Flow

Free cash flow has been inconsistent, with significant fluctuation over the years. The operating cash flow to net income ratio is not available for the latest period, making assessment difficult. The company must focus on stabilizing its free cash flow to support future investments and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.33B	1.30B	1.27B	1.10B	925.33M	642.30M
Gross Profit	963.81M	981.43M	995.64M	873.93M	747.53M	513.14M
EBITDA	134.22M	271.87M	253.46M	445.78M	397.59M	111.88M
Net Income	71.91M	222.39M	263.24M	325.34M	292.47M	216.09M
Balance Sheet
Total Assets	5.33B	4.90B	4.70B	3.69B	3.18B	2.95B
Cash, Cash Equivalents and Short-Term Investments	1.39B	1.18B	1.18B	833.79M	1.48B	1.14B
Total Debt	3.91M	4.98M	9.30M	9.67M	15.67M	185.98M
Total Liabilities	1.60B	1.42B	1.37B	769.05M	653.61M	596.06M
Stockholders Equity	3.77B	3.49B	3.37B	2.90B	2.50B	2.34B
Cash Flow
Free Cash Flow	572.83M	38.46M	125.36M	52.84M	145.57M	180.15M
Operating Cash Flow	610.06M	321.46M	418.05M	388.32M	488.85M	338.53M
Investing Cash Flow	-566.23M	-517.53M	-453.88M	-458.47M	-86.76M	-341.63M
Financing Cash Flow	-92.84M	-116.97M	182.71M	-215.20M	-256.38M	674.66M

LifeTech Scientific Corporation Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1302, the sentiment is Negative. The current price of 1.9 is below the 20-day moving average (MA) of 2.05, below the 50-day MA of 1.98, and above the 200-day MA of 1.75, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.84 is Neutral, neither overbought nor oversold. The STOCH value of 5.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1302.

LifeTech Scientific Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2190	58 Neutral	HK$7.83B	46.19	4.99%	0.46%	35.01%	483.73%
2172	58 Neutral	HK$6.69B	30.22	11.79%	1.45%	-5.18%	-9.69%
1302	57 Neutral	HK$8.51B	110.67	1.98%	―	3.42%	-70.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2160	43 Neutral	HK$2.70B	509.09	0.22%	―	-4.38%	―
0853	40 Neutral	$21.88B	-16.56	-24.77%	―	-1.04%	60.66%

LifeTech Scientific Corporation Corporate Events

LifeTech’s G-Branch™ Stent Graft System Gains Approval in China

LifeTech Scientific Corporation announced that its G-Branch™ thoracoabdominal artery stent graft system has received official registration approval from the China National Medical Products Administration. This device, designed for the treatment of complex thoracoabdominal aortic aneurysms, offers a less invasive alternative to traditional surgery, which is associated with high risks and complications. The product’s innovative design and successful clinical trials highlight LifeTech’s commitment to advancing endovascular treatment options, potentially impacting the treatment landscape for aortic aneurysms in China.

The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

LifeTech Scientific Unveils Promising Two-Year Clinical Results for Innovative Coronary Scaffold

LifeTech Scientific Corporation announced the successful completion of two-year follow-up results for its Phase II and Phase III clinical studies of the IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System. The studies demonstrated that the IBS® Coronary Scaffold achieved non-inferiority in primary endpoints compared to existing solutions, with low rates of thrombotic events. This positions the product as a competitive alternative to current drug-eluting metal stents, receiving positive feedback from cardiovascular experts at the Transcatheter Cardiovascular Therapeutics 2025 conference.

The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

LifeTech Scientific Reports Mixed Interim Results Amidst Increased Expenses

LifeTech Scientific Corporation announced its interim results for the six months ending June 30, 2025, reporting a turnover of approximately RMB676.7 million, a 3.7% increase from the previous year. However, the company’s net profit, after accounting for non-recurring items, saw a significant decrease of 73.2% compared to the same period in 2024, primarily due to changes in financial asset gains and increased share-based payment expenses.

The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

LifeTech’s Innovative Heart Device Gains Regulatory Approval

LifeTech Scientific Corporation has announced that its Congenital Heart Defect Occluder has been admitted into the National Medical Products Administration’s Special Examination and Approval Procedure for Innovative Medical Devices. This marks the company’s 16th product to achieve such recognition, highlighting its commitment to advancing medical technology for congenital heart diseases. The occluder, designed with a full nitinol metal structure, offers a bidirectional release mechanism, enhancing treatment options for patients with patent ductus arteriosus (PDA). This development is expected to expedite the product’s registration and launch, benefiting PDA patients and expanding LifeTech’s product portfolio.

The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

LifeTech Scientific Announces Board Meeting to Review Interim Results

LifeTech Scientific Corporation has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of the year. The meeting will also consider the payment of an interim dividend and other business matters, potentially impacting the company’s financial strategy and shareholder returns.